Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are researching adipose-derived stem cell therapy in Japan, you will soon run into an unfamiliar phrase: the regulatory framework for regenerative medicine. For many international patients, it is not obvious what this framework is, what it covers, or why it should matter when choosing a clinic. This article explains the basics in plain language, so that you can arrive at a consultation with better questions. It is general information, not medical advice, and it does not replace an assessment by a physician.
The short answer: a legal framework sits behind every treatment of this kind
In Japan, regenerative medicine that uses a patient’s own cells is not left to each clinic’s discretion. It is handled under a dedicated law, commonly known in English as the Act on the Safety of Regenerative Medicine. In simple terms, a medical institution that wishes to offer a cell-based treatment must prepare a plan describing the treatment, have that plan reviewed by a designated committee, and submit it to the authorities before treatment can be provided. Cell culture is also expected to take place at a facility that meets defined requirements.
The existence of this framework does not mean that a treatment is guaranteed to work for any particular person, and it is not a promise that nothing will go wrong. What it does provide is a structure for review, documentation and reporting. For a patient, that structure is one useful lens for judging how seriously a clinic treats the process.
How the framework relates to adipose-derived stem cell therapy
Adipose-derived stem cell therapy follows a sequence that is easy to describe. A very small amount of your own fat tissue is collected, mesenchymal stem cells contained in it are cultured and expanded at a specialized facility, and the cells are later returned to your body by intravenous infusion. Because the cells are processed outside the body before they are returned, this type of treatment falls within the scope of regenerative medicine regulation in Japan.
This is different from taking a conventional medicine that has completed the standard approval pathway for a particular disease. Treatments provided under the regenerative medicine framework are generally offered as self-pay care, and research on their effects is still developing worldwide. Mesenchymal stem cells have been reported to release anti-inflammatory substances and growth factors, but results from studies vary, and findings from one study should not be generalized to every individual.
What this means for you as a patient
Understanding the framework helps you separate three different questions that are often blended together in online discussions. The first is whether a clinic is operating within the rules that apply to it. The second is whether a treatment is suitable for your own health situation. The third is whether the expected benefit justifies the cost, time and risk for you. The law speaks mainly to the first question. The second and third can only be answered through a medical consultation.
It also means that adipose stem cell therapy is positioned as a treatment option to consider alongside your existing medical care, not a replacement for standard treatment. If you are being treated for a chronic condition, it is sensible to keep your current doctors informed and to bring your records to any new consultation.
Questions worth asking before you decide
A consultation is the right place to turn general knowledge into a personal decision. The following questions are a practical starting point, and a good clinic should be willing to discuss each of them openly.
- Is this treatment provided under a regenerative medicine plan that has been submitted in accordance with Japanese law, and can the clinic explain it in terms you understand?
- Where are the cells cultured, and how is the process managed from collection to infusion?
- What are the possible risks and side effects, and how are they monitored afterward?
- What is the total cost, including consultation, fat collection, culture and infusion, and what is not covered?
- Is your condition a reasonable candidate for this approach, or are there reasons for caution in your case?
- How will the clinic coordinate with your current doctors, and what follow-up can you expect once you return home?
Because this is a self-pay treatment outside national health insurance, fees, risks, side effects and eligibility must be confirmed with a doctor after an individual examination. Be cautious about any source that promises a specific result or presents the treatment as a cure.
Planning a consultation in Osaka as an international patient
Grand Green Osaka Umekita Clinic, located in the Umeda area of Osaka, provides adipose-derived stem cell therapy as a self-pay regenerative treatment and offers an information page for international patients. Fat collection is performed under local anesthesia and both collection and infusion are done on an outpatient basis, which can make scheduling around work or travel more manageable, although the exact timeline depends on your situation and should be confirmed with the clinic.
If you are traveling from overseas, it helps to prepare in advance. Gather your medical history, a list of current medicines and recent test results, and write down your questions about the regulatory framework, cell culture, risks and costs. Clear communication matters in a field with this much technical vocabulary, so use the clinic’s multilingual information to review the treatment flow before you arrive.
Summary
Japan’s regenerative medicine law gives adipose-derived stem cell therapy a defined structure of review and oversight, and knowing this helps you ask sharper questions. It does not predict how a treatment will work for you, and it does not remove the need for a careful medical decision. Consider the treatment as one possible option, discuss costs, risks and side effects openly, and keep your current doctors involved. If you would like to learn more, the treatment page and the consultation channels of Grand Green Osaka Umekita Clinic are a practical place to begin, and a physician’s examination is the step that turns general information into advice for your own case.
- Know the legal framework
- Prepare your questions
- Confirm self-pay costs
- Decide with your doctor
This figure is a conceptual diagram summarizing the article
References
- PubMed: Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. (2025)
- PubMed: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). (2016)
- PubMed: Regulatory perspectives of Japan. (2015)
- PubMed: Basic Points to Consider for Cell Storage under the Act on the Safety of Regenerative Medicine in Japan. (2025)
- PubMed: Reflection on the enactment and impact of safety laws for regenerative medicine in Japan. (2021)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.